The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
Open accessAbstract
Purpose: Panitumumab, a fully human antibody targeting the epidermal growth factor receptor, is active in patients with metastatic colorectal cancer (mCRC). This trial evaluated panitumumab added to bevacizumab and chemotherapy (oxaliplatin- and irinotecan-based) as first-line treatment for mCRC. Patients and Methods: Patients were randomly assigned within each chemotherapy cohort to bevacizumab and chemotherapy with or without panitumumab 6 mg/kg every 2 weeks. The primary end point was progression-free survival (PFS) within the oxaliplatin cohort. Tumor assessments were performed every 12 weeks and reviewed centrally. Results: A total of 823 and 230 patients were randomly assigned to the oxaliplatin and irinotecan cohorts, respectively. Panitumumab was discontinued after a planned interim analysis of 812 oxaliplatin patients showed worse efficacy in the panitumumab arm. In the final analysis, median PFS was 10.0 and 11.4 months for the panitumumab and control arms, respectively (HR, 1.27; 95% CI, 1.06 to 1.52); median survival was 19.4 months and 24.5 months for the panitumumab and control arms, respectively. Grade 3/4 adverse events in the oxaliplatin cohort (panitumumab v control) included skin toxicity (36% v 1%), diarrhea (24% v 13%), infections (19% v 10%), and pulmonary embolism (6% v 4%). Increased toxicity without evidence of improved efficacy was observed in the panitumumab arm of the irinotecan cohort. KRAS analyses showed adverse outcomes for the panitumumab arm in both wild-type and mutant groups. Conclusion: The addition of panitumumab to bevacizumab and oxaliplatin- or irinotecan-based chemotherapy results in increased toxicity and decreased PFS. These combinations are not recommended for the treatment of mCRC in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The PACCE study evaluated the addition of panitumumab to chemotherapy and bevacizumab, showing that the combined use of two biological agents may result in adverse outcomes irrespective of RAS mutation status [19].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Self-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Research works printed but not linked: 3
- Mitchell EP, 10th Annual World Congress of Gastrointestinal Cancers
- Van Cutsem E, 2007, J Clin Oncol, 25, 18s
- Ciardiello F, 2000, Clin Cancer Res, 6, 3739
Cited by
Sorted by citations
Items 301–400 of 849
Emerging antibody combinations in oncology
Demarest, S. J., Hariharan, K., & Dong, J. (2011) · mAbs · doi:10.4161/mabs.3.4.16615 · Cited by 30
Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab
Rodríguez, J., Viúdez, A., Ponz‐Sarvisé, M., Gil-Aldea, I., Chopitea, A., García‐Foncillas, J., & Bazo, I. G. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.07.005 · Cited by 31
Frank, M. R., & Mittendorf, T. (2013) · PharmacoEconomics · doi:10.1007/s40273-012-0017-2 · Cited by 28
EGFR signaling in colorectal cancer: a clinical perspective
Frattini, M., Saletti, P., Molinari, F., & Dosso, S. D. (2015) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s49002 · Cited by 32
Development of Molecular Biomarkers in Individualized Treatment of Colorectal Cancer
Mattos‐Arruda, L. D., Dienstmann, R., & Tabernero, J. M. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.03.030 · Cited by 30
Bekaii‐Saab, T., & Wu, C. S.-Y. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.01.001 · Cited by 29
Grothey, A. F. (2010) · Oncology · doi:10.1159/000323491 · Cited by 29
Garrett, C. R., Siu, L. L., El-Khoueiry, A. B., Buter, J., Rocha‐Lima, C., Marshall, J. L., LoRusso, P. M., Major, P. P., Chemidlin, J., Mokliatchouk, O., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.182 · Cited by 29
Self-citationAlfonso, P. G., Grande, E., Polo, E., Afonso, R., Reina, J. J., Jorge, M., Campos, J. M., Martínez, V., Ángeles, C., & Montagut, C. O. (2014) · Angiogenesis · doi:10.1007/s10456-014-9433-6 · Cited by 29
Valuing end-of-life care in the United States: the case of new cancer drugs
Sorenson, C. (2012) · Health Economics Policy and Law · doi:10.1017/s1744133112000217 · Cited by 28
Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers
Desai, M. D., Saroya, B. S., & Lockhart, A. C. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.761972 · Cited by 28
Petrelli, F., Coinu, A., Ghilardi, M., Cabiddu, M., Zaniboni, A., & Barni, S. (2013) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3182a2d7b8 · Cited by 28
Power, D. G., Shah, M. A., Asmis, T. R., García, J. J., & Kemeny, N. E. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9268-y · Cited by 28
Vatalanib in Advanced Colorectal Cancer: Two Studies With Identical Results
Sobrero, A. F., & Bruzzi, P. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2429 · Cited by 28
Cetuximab after bevacizumab in metastatic colorectal cancer: Is it the best sequence?
Norguet, E., Dahan, L., Gaudart, J., Gasmi, M., Ouafik, L., & Seitz, J. (2011) · Digestive and Liver Disease · doi:10.1016/j.dld.2011.06.002 · Cited by 27
Mammatas, L. H., Verheul, H. M. W., Hendrikse, N. H., Yaqub, M. M., Lammertsma, A. A., & van Oordt, C. W. M. D. H. (2014) · Cellular Oncology · doi:10.1007/s13402-014-0194-4 · Cited by 27
Dotan, E., Meropol, N. J., Burtness, B. A., Denlinger, C. S., Lee, J., Mintzer, D. M., Zhu, F., Ruth, K. J., Tuttle, H., Sylvester, J., et al. (2012) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-012-9368-3 · Cited by 28
Targeted Therapeutic Agents for Colorectal Cancer
Chee, C. E., & Sinicrope, F. A. (2010) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2010.08.017 · Cited by 27
Chirila, C., Odom, D. M., Devercelli, G., Khan, S., Sherif, B. N., Kaye, J. A., Molnár, I., & Sherrill, B. H. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1349-7 · Cited by 27
Engineered Proteins Pull Double Duty
Cochran, J. R. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000276 · Cited by 27
Christoffersen, T., Guren, T. K., Spindler, K. G., Dahl, O., Lønning, P. E., & Gjertsen, B. T. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.009 · Cited by 26
Rash Rates with EGFR Inhibitors: Meta-Analysis
Mittmann, N., & Seung, S. J. (2011) · Current Oncology · doi:10.3747/co.v18i2.605 · Cited by 27
Tabernero, J. M., & Macarulla, T. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3098 · Cited by 27
Stein, A., Glockzin, G., Wienke, A., Arnold, D., Edelmann, T., Hildebrandt, B., Hollerbach, S. H., Illerhaus, G., Königsrainer, A., Richter, M., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-356 · Cited by 27
Progression-Free Survival as a Primary Endpoint in Clinical Trials of Metastatic Colorectal Cancer
Gill, S., Berry, S. R., Biagi, J., Butts, C., Buyse, M. E., Chen, E., Jonker, D., Marginean, C. E., Samson, B., Stewart, J., et al. (2011) · Current Oncology · doi:10.3747/co.v18is2.941 · Cited by 27
The Challenge of Metastatic Colorectal Cancer
Cidón, E. U. (2010) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s5214 · Cited by 26
Treatment recommendations for metastatic colorectal cancer
Aranda, E., Abad, A., Carrato, A., Cervantes, A. M. R., García‐Foncillas, J., Alfonso, P., García‐Carbonero, R., España, A. G., Tabernero, J. M., & Díaz‐Rubio, E. (2011) · Clinical & Translational Oncology · doi:10.1007/s12094-011-0636-7 · Cited by 26
Ibrahim, E. M., Zekri, J., & Sadiq, B. M. B. (2010) · International Journal of Colorectal Disease · doi:10.1007/s00384-010-0927-4 · Cited by 27
Starling, N., Mazon, F. J. V., Cunningham, D., Chau, I., Tabernero, J. M., Ramos, F. J., Iveson, T. J., Saunders, M. P., Aranda, E., Countouriotis, A., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr046 · Cited by 26
Endothelial cell in tumor angiogenesis: Origins, mechanisms, and therapeutic implication
Han, Y., Zhu, B., & Meng, S. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101611 · Cited by 31
Predictive Molecular Classifiers in Colorectal Cancer
Bohanes, P. O., LaBonte, M. J., Winder, T., & Lenz, H. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.05.012 · Cited by 26
Abdel-Rahman, O. M. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.07.005 · Cited by 25
Blank‐Landeshammer, B., Richard, V. R., Mitsa, G., Marques, M., LeBlanc, A. M., Kollipara, L., Feldmann, I., du Tertre, M. C., Gambaro, K., McNamara, S., et al. (2019) · Cancers · doi:10.3390/cancers11121907 · Cited by 25
The HER family as therapeutic targets in colorectal cancer
Ye, P., Wang, Y., Li, R., Chen, W., Wan, L., & Cai, P. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103681 · Cited by 27
Cetuximab and panitumumab: are they interchangeable?
Kim, R. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70312-2 · Cited by 25
Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer
Gill, S., Berry, S. R., Biagi, J. J., Butts, C. A., Buyse, M. E., Chen, E., Jonker, D. J., Maginean, C., Samson, B., Stewart, J., et al. (2011) · Current Oncology · doi:10.3747/co.v18i0.958 · Cited by 25
Metastatic colorectal cancer: recent advances in its clinical management
Barugel, M. E., Vargas, C., & Krygier, G. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.143 · Cited by 26
Neuzillet, C., Rousseau, B., Kocher, H. M., Bourget, P., & Tournigand, C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.028 · Cited by 25
González, J. M., Ogale, S. S., Morlock, R., Posner, J., Hauber, B., Sommer, N., & Grothey, A. A. (2017) · Cancer Management and Research · doi:10.2147/cmar.s125245 · Cited by 25
Li, Y., Chen, X., Li, W., Ye, Y., Du, X., Sun, S., Liu, L., & Zhang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684309 · Cited by 24
Integrating anti-EGFR therapies in metastatic colorectal cancer.
Haraldsdóttir, S., & Bekaii‐Saab, T. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2013.028 · Cited by 24
Peeters, M., Cohn, A. L., Köhne, C., & Douillard, J. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.06.010 · Cited by 24
Self-citationNakayama, I., Shinozaki, E., Matsushima, T., Wakatsuki, T., Ogura, M., Ichimura, T., Ozaka, M., Takahari, D., Suenaga, M., Chìn, K., et al. (2017) · BMC Cancer · doi:10.1186/s12885-016-2994-6 · Cited by 24
Abdel-Rahman, O. M. (2019) · International Journal of Colorectal Disease · doi:10.1007/s00384-019-03430-y · Cited by 24
Inflammation and Gastrointestinal Cancers
Jankowski, J. A. (2011) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-03503-6 · Cited by 24
Treatment of metastatic colorectal cancer: focus on panitumumab
Hawkes, E. A., Tay, R. Y., & Wong, R. (2015) · Cancer Management and Research · doi:10.2147/cmar.s71821 · Cited by 24
Wong, N. S., Fernando, N. H., Nixon, A. B., Cushman, S. M., Aklilu, M., Bendell, J. C., Morse, M. A., Blobe, G. C., Ashton, J., Pang, H., et al. (2011) · PubMed · Cited by 25
KRAS Mutation Screening in Colorectal Cancer: From Paper to Practice
Fakih, M. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.003 · Cited by 24
Optical molecular imaging and its emerging role in colorectal cancer
Sheth, R. A., & Mahmood, U. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00195.2010 · Cited by 24
Bruera, G., Cannita, K., Giacomo, D. D., Lamy, A., Troncone, G., Mas, A. D., Coletti, G., Frébourg, T., Sabourin, J. C., Tosi, M., et al. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-135 · Cited by 23
Sequencing of treatment in metastatic colorectal cancer: Where to fit the target
Temraz, S. N. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i8.1993 · Cited by 24
Kummar, S., Gutierrez, M. E., Chen, A. P., Turkbey, I. B., Allen, D. E., Horneffer, Y. R., Juwara, L., Cao, L., Yu, Y., Kim, Y. S., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.12.016 · Cited by 23
Chung, C. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211005525 · Cited by 24
Monoclonal Antibody Therapy For Malignant Glioma
Chen, K. S., & Mitchell, D. A. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3146-6_10 · Cited by 25
Mésange, P., Bouygues, A., Ferrand, N., Sabbah, M., Escargueil, A. E., Savina, A., Chibaudel, B., Tournigand, C., André, T., de Gramont, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3187 · Cited by 22
APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes
Thota, R., Yang, M., Pflieger, L. T., Schell, M. J., Rajan, M., Davis, T. B., Wang, H., Presson, A. P., Pledger, W. J., & Yeatman, T. J. (2021) · Cancers · doi:10.3390/cancers13215394 · Cited by 22
Cohen, R., Raeisi, M., Chibaudel, B., Shi, Q., Yoshino, T., Zalcberg, J. R., Adams, R., Cremolini, C., Cutsem, E. V., Heinemann, V., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114160 · Cited by 24
Self-citationPanitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer
Addeo, R., Caraglia, M., Cerbone, D., Frega, N., Cimmino, G., Abbruzzese, A., & Prete, S. D. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.28 · Cited by 22
Dysphonia induced by anti-angiogenic compounds
Saavedra, E., Hollebecque, A., Soria, J., & Hartl, D. M. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0049-2 · Cited by 22
Redman, M. W., Goldman, B. H., LeBlanc, M. L., Schott, A. F., & Baker, L. H. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2939 · Cited by 23
Yuan, S., Yang, W.-B., Shi, L., Ye, Z., Shi, H., & Zhou, Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035629 · Cited by 22
Recent Advances Relating to the Clinical Application of Naked Monoclonal Antibodies in Solid Tumors
Argyriou, A. A., & Kalofonos, H. P. (2009) · Molecular Medicine · doi:10.2119/molmed.2009.00007 · Cited by 22
Emerging Trends for Radioimmunotherapy in Solid Tumors
Jain, M., Gupta, S., Kaur, S., Ponnusamy, M. P., & Batra, S. K. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2013.1523 · Cited by 21
Personalized treatment for advanced colorectal cancer: KRAS and beyond
Karapetis, C. S., & Patel, G. S. (2013) · Cancer Management and Research · doi:10.2147/cmar.s35025 · Cited by 20
Merla, A., & Goel, S. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/387172 · Cited by 22
Chemotherapy for the Elderly Patient With Colorectal Cancer
Power, D. G., & Lichtman, S. M. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181e07690 · Cited by 21
Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer
Heinemann, V., & Hoff, P. M. (2010) · Oncology · doi:10.1159/000314993 · Cited by 21
Bevacizumab in colorectal cancer: current and future directions
Yeung, Y. H., & Tebbutt, N. C. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.104 · Cited by 21
Integration of Biologic Agents With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer
Jain, V. K. S., Hawkes, E. A., & Cunningham, D. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.04.001 · Cited by 21
Palliative treatment of unresectable metastatic colorectal cancer
Fornaro, L., Masi, G., Loupakis, F., Vasile, E., & Falcone, A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903427997 · Cited by 21
Ketzer, S., Schimmel, K. J. M., Koopman, M., & Guchelaar, H. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0590-9 · Cited by 23
Repurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant APC and TP53 Subpopulations
Yang, M., Schell, M. J., Loboda, A. P., Nebozhyn, M., Li, J., Teer, J. K., Pledger, W. J., & Yeatman, T. J. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-1383 · Cited by 21
Pharmacological cancer treatment and venous thromboembolism risk
Martín, A. J. M., Ramírez, S. P., Morán, L. O., Zamorano, M. R., Viñuela-Benéitez, M. C., Aparicio, I., Escobar, I. G., & Soria, J. M. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa004 · Cited by 21
Glynne‐Jones, R., Hadaki, M., & Harrison, M. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2013.037 · Cited by 21
Abdel-Rahman, O. M., & Karachiwala, H. (2019) · International Journal of Colorectal Disease · doi:10.1007/s00384-019-03389-w · Cited by 20
Larbouret, C., Gros, L., Pèlegrin, A., & Chardès, T. (2021) · Cancers · doi:10.3390/cancers13184620 · Cited by 20
Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia
Bichsel, K. J., Gogia, N., Malouff, T. D., Peña, Z. G., Forney, E., Hammiller, B., Watson, P. A., & Hansen, L. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069368 · Cited by 21
Azad, N. S., Dasari, A. N., Arcaroli, J. J., Taylor, G., Laheru, D. A., Carducci, M. A., McManus, M. C., Quackenbush, K. S., Wright, J. J., Hidalgo, M. M., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9820-z · Cited by 20
Giuliani, J., & Bonetti, A. V. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.07.002 · Cited by 20
Li, J., & Yan, H. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3644-2 · Cited by 20
Management of advanced colorectal cancer, part 2
Cersosimo, R. J. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110532b · Cited by 20
Nixon, A. B., Sibley, A. B., Liu, Y., Hatch, A. J., Jiang, C., Mulkey, F., Starr, M. D., Brady, J. C., Niedzwiecki, D., Venook, A. P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2389 · Cited by 20
Teng, L., He, H., Cui, C., Jin, Li, & Wang (2012) · OncoTargets and Therapy · doi:10.2147/ott.s29719 · Cited by 19
Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer
Woo, J., Palmisiano, N. D., Tester, W., & Leighton, J. C. (2013) · Cancer · doi:10.1002/cncr.27994 · Cited by 19
Monoclonal antibodies for targeted therapy in colorectal cancer.
Banerjee, S., & Flores‐Rozas, H. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.8.11403 · Cited by 21
Targeted Therapies for Solid Tumors
Stoffel, A. (2010) · BioDrugs · doi:10.2165/11535880-000000000-00000 · Cited by 19
Colorectal cancer: cetuximab,KRAS,BRAF,PIK3CAmutations and beyond
Katsios, C. G., Ziogas, D. E., & Roukos, D. H. (2010) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.10.62 · Cited by 19
Monoclonal Antibody Therapy for Cancer
Rader, C. M. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-980-2_3 · Cited by 19
Chen, C. T., Bartolomeo, M. D., Corallo, S., Strickler, J. H., & Goyal, L. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280871 · Cited by 18
Burudpakdee, C., Zhao, Z., Munakata, J., Gao, S., Trochlil, K., & Barber, B. (2011) · Journal of Medical Economics · doi:10.3111/13696998.2011.650774 · Cited by 17
Giuliani, J., & Bonetti, A. V. (2018) · International Journal of Colorectal Disease · doi:10.1007/s00384-018-3158-8 · Cited by 18
Wang, Y., Dong, L., Bi, Q., Li, X., Wu, D., Ge, X., Zhang, X., Fu, J., Zhang, C., Wang, C., et al. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0164-3 · Cited by 18
Nestor, M., Sundström, M., Anniko, M., & Максимилианович, Т. В. (2010) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2010.06.014 · Cited by 18
Vidaurre, T., Wilkerson, J., Simon, R. M., Bates, S. E., & Fojo, T. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181b9d37b · Cited by 18
Pauw, I. D., Wouters, A., den Bossche, J. V., Peeters, M., Pauwels, P., Deschoolmeester, V., Vermorken, J. B., & Lardon, F. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.014 · Cited by 17
Giopanou, I., & Pintzas, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102859 · Cited by 17
The “angiogenetic ladder”, step-wise angiogenesis inhibition in metastatic colorectal cancer
Giampieri, R., Scartozzi, M., Prete, M. D., Fulli, A., Faloppi, L., Bianconi, M., Maccaroni, E., & Cascinu, S. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.004 · Cited by 17
Ibrahim, E. M., & Abouelkhair, K. M. (2011) · Medical Oncology · doi:10.1007/s12032-010-9760-4 · Cited by 17
Panitumumab: A Summary of Clinical Development in Colorectal Cancer and Future Directions
Argilés, G., Dienstmann, R., Élez, E., & Tabernero, J. M. (2012) · Future Oncology · doi:10.2217/fon.12.20 · Cited by 17
Hofheinz, R., Petersen, V., Kindler, M., Schulze, M., Seraphin, J., Hoeffkes, H., Valdix, A., Schroeder, J., Herrenberger, J., Stein, A., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-761 · Cited by 17
Metadata
- Authors
- Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., Deeter, R., Shahin, S., & Amado, R. G.
- Affiliations
- Amgen (United States) (US)
- Venue
- Journal of Clinical Oncology
- Published
- 2009-02-10
- Volume
- 27
- Issue
- 5
- Pages
- 672-680
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2002226820
- Cited by
- 850
- References
- 30
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 19 · 2023: 10 · 2022: 21 · 2021: 15 · 2020: 29 · 2019: 29 · 2018: 26 · 2017: 38 · 2016: 44 · 2015: 57 · 2014: 56 · 2013: 88 · 2012: 101
- FWCI
- 53.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- metastatic colorectal cancer, panitumumab, bevacizumab, oxaliplatin, irinotecan, EGFR inhibition, first-line chemotherapy, progression-free survival, treatment toxicity, KRAS mutation, anti-EGFR monoclonal antibody
- MeSH terms
- Bevacizumab, Irinotecan, Oxaliplatin, Panitumumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Colorectal Neoplasms, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
